ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany

Similar documents
How do I use mechanical debulking for the treatment of arterial occlusions

Rotarex mechanical debulking: The Leipzig experience in patients

Rotarex mechanical thrombectomythe first line option for thrombotic occlusions?

Atherectomy with thrombectomy of. Rotarex S : The Leipzig experience

Mechanical thrombectomy in peripheral interventions: A multitask and effective tool in a widening scenario. Current evidence and technical tips.

Update from Korea on the Lutonix SFA registry 12 month data

The Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology

Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry

Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort

BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions

The Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD

DCB in my practice: How the evidence influences my strategy. Yang-Jin Park

Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD

Maximizing Outcomes in a complex population with Drug-coated balloon

OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD

COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert

Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?

12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany

2-YEAR DATA SUPERA POPLITEAL REAL WORLD

Plaque scoring in calcified lesions

Atherectomy: Jetstream and Directional. George S. Chrysant, M.D.

Treating in-stent occlusions with the Rotarex catheter : The ROBINSON study

Hybrid Procedures for Peripheral Obstructive Disease - Step by Step -

Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-

ILLUMENATE FIH Direct DCB Cohort 12-Month Results

The essentials for BTK procedures: wires, balloons, what else

SFA CTO Lesion Management laser or directional atherectomy?

January 23, Vascular and oncological interventional radiology Paris Descartes University

Long-term Zilver PTX Data from Japan: 5-year Results in the Real World

Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?

Straub Endovascular System &

Update on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany

Dierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany

Clinical benefits on DES Patient s perspectives

2 Year Results from the MDT SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA

Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA

Comparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions

RANGER SFA REGISTRY Interim Analysis. Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators

Massimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany

Step by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery

Long-term results with interwoven nitinol stents vs. BMS vs. DCB

Excimer Laser angioplasty for femoro-popliteal disease. Sendai Kousei Hospital, Tokyo Kamata Hospital Naoto Inoue MD, FSCAI, FJCC, FAHA

DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes

Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry

Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)

Latest Insights from the LEVANT II study and sub-group analysis

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan

The latest evidences from the DES trials in peripheral arterial disease

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

Aggressive BTK Revascularization and Advanced Wound Care - Patient Specific Therapy Concepts

Michael K.W. Lichtenberg, MD

TOBA Trial 12 months Results

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report

Brachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts

Final Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)

Turbo-Power. Laser atherectomy catheter. The standard. for ISR

Shockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany

Update on the Ranger clinical trial programme

Drug-Eluting Balloon Angioplasty versus Bare Metal Stents for Femoropopliteal Disease in Real-World Experience

Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

The Supera stent In retrograde vascular access for SFA ostium treatment: The SUPRA-FAST Registry

Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial

Alternative concepts for drug delivery in BTK arteries the LIMBO project

One Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller

Update on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria

Could a combination of DCB + stent be the answer in complex SFA lesions

LUTONIX DCB in BTK Update on the BTK clinical program & single center experience

New approaches for drug delivery in BTK arteries

The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience

Novel distal popliteal artery puncture technique in supine position for chronic femoropopliteal arterial occlusion; frontal popliteal puncture

Novel concept for drug delivery in infrapopliteal arteries The LIMBO trial

Klinikum Rosenheim Department of Diagnostic and Interventional Radiology

Do we really need a stent in long SFA lesions? No: DEB is the answer

EffPac - Trial: Assessment of the Effectiveness of DCB versus POBA in the SFA Ulf Teichgräber, MD, MBA

Six Month Results of the Global BIOLUX P-III All-Comers Registry using Drug Coated Balloon in Infra-Inguinal Artery Disease

Adventitial Drug Therapy Below-the-Knee: Update on LIMBO and TANGO

MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together

Lutonix DCB in BTK Update on the BTK real world registry and RCT

DISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.

Nicolas W Shammas, MD, MS

The LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint

Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy

Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD

The importance of scientific evidence. Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern

Hiroshi Ando, MD Kasukabe Chuo General Hospital Saitama, Japan

Safety and Efficacy of Distal Superficial Femoral Artery Puncture for Femoropopliteal Occlusive Lesions

Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis

Vessel preparation with scoring balloons prior to DCB or stenting

Importance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study

Disclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA

Koen Keirse, MD RZ Tienen, Belgium

The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium

SFA In-stent Restenosis

Why and how to prep the vessel

Transcription:

ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany

Disclosure Speaker name: Sven Bräunlich I have the following potential conflicts of interest to report: x Consulting (Abbott, Bard, Cook, Straub) Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) I do not have any potential conflict of interest

The Problem of In-stent Restenosis and Reocclusion Endovascular revascularization of long femoropopliteal lesions is well established today Stents improve patency What to do in case of restenosis or reocclusion?

The Problem of In-stent Restenosis and Reocclusion

The Problem of In-stent Restenosis and Reocclusion Classification of ISR In-Stent Occlusions are at high risk for recurrent ISR after re-intervention

The Problem of In-stent Restenosis and Reocclusion Specific endovascular strategies are needed to open the stent BEFORE angioplasty/ptx application

The Problem of In-stent Restenosis and Reocclusion Werner et al. JEVT 2012

Rotarex S Catheter (Straub-Medical) Detachment (up to 1 cm/s) Suction Fragmentation Transport

Rotarex mechanical debulking: The Leipzig experience in 1.800+ patients - Single center registry: - Use of a debulking device (Rotarex) in PAOD patients - Safety and efficacy - Consecutive patient enrollment - Real world scenario - 1.809 patients treated (from 1/2005 11/2013) - 1.572 patients were analyzable (86,9%)

Rotarex mechanical debulking: The Leipzig experience in 1.800+ patients Intervention Feature - Native virgin arteries - Surgical bypasses - Redo procedures - In-stent procedures 1203 Procedures

Rotarex mechanical debulking: The Leipzig experience in 1.800+ patients Intervention Feature - Native virgin arteries - Surgical bypasses - Redo procedures - In-stent procedures 338 Procedures

Rotarex for chronic ISR In-stent occlusion right SFA and PA

Rotarex for chronic ISR Result after 3 Rotarex passages

Rotarex for chronic ISR Result after additional DCB angioplasty

Rotarex mechanical debulking in In-stent procedures: Demographic characteristics (n=338) Age, Mean ± SD (n) 68.1 ± 13.6 Male gender, n(%) 217 (64.2) Medical History, n(%) Obesity 113 (33.4) Smoking 166 (49.1) Dyslipidemia 263 (77.8) Diabetes 147 (43.5) Hypertension 275 (81.4) Coronary Artery Disease 110 (32.6) Cerebrovascular disease 41 (12.1) Renal Impairment 46 (13.6) Dialysis 5 (1.5) Previous anticoagulation 24 (7.2) Table 1. Clinical characteristics of 338 patients treated with mechanical debulking for in-stent procedures.

Rotarex mechanical debulking in In-stent procedures: Onset of symptoms (n=338) Acute ( <14 days ) 73 (21.6%) Subacute ( < 3 months ) 114 (33.7%) Chronic ( > 3 months ) 151 (44.6%)

Rotarex mechanical debulking in In-stent procedures: Clinical status Rutherford class on admission Rutherford Score Patient with events, n(%) 0 0 1 2 (0.6) 2 58 (17.2) 3 212 (62.7) 4 28 (8.3) 5 38 (11.2) 6 0 (0.0) Total 338 (100) Table 2. Baseline Rutherford scores among patients at enrollment Debulking for in-stent procedures

Rotarex mechanical debulking in In-stent procedures: Angiographic and procedural characteristics Total Vascular access sites 338 Antegrade 118 (34,9%) Crossover 176 (52.1%) Retrograde 44 (13%) Sheath diameter device (French) 6 136 (40.2) 8 202 (59.8) Mean lesion length (cm) 16.3 (4.7-24.8) Intervention area Iliac 44 (13%) SFA 139 (41.1%) Popliteal 39 (11.5%) SFA + Popliteal 101 (29.9%) Proximal BTK 6 (1.8%) Other 9 (2.7%) Table 3. Overall Angiographic and procedural characteristics among 338 patients treated with mechanical debulking devices for in-stent procedures.

Rotarex mechanical debulking in In-stent procedures: Angiographic and procedural characteristics Type of lesion (complain symptoms) n (%) Calcification 327 * No/mild 72 (22%) Moderate 156 (46.2%) Severe 99 (31.8%) Intervention Feature 338 De-novo lesions 54 (15.9%) Previous Balloon Angioplasty 161 (47.6%) * Loss of 11 patients, due to inadequate images

Rotarex mechanical debulking in In-stent procedures: Acute results Procedural success rate: 326 (96.4% ) Main performed procedure Rotarex Debulking alone: 68 (20.9%) Rotarex Debulking + PTA: 195 (59.8%) Additional Stenting: 41 (12.6%) Additional Thrombolysis: 45 (13.8%) Associated BTK treatment: 75 (23.0%) Mean time follow-up: 12 ± 2.4 months

Rotarex mechanical debulking in In-stent procedures: Acute results - Complications Major Adverse Events (MAE) to 30 days post-intervention MAE All events n (%) Perforation 14 (4.1%) Bleeding 15 (4.4%) Dissection 10 (2.9%) Acute closure 7 (2.2%) Emboli 22 (6.5%) Infection 8 (2.1%)

Rotarex mechanical debulking in In-stent procedures: Clinical Follow-up: 30-day Results Major Adverse Events (MAE) to 30 postoperative day MAE Events (%) Death 4 1.2 MI 6 1.8 TLR 9 2.7 TVR 3 0.9 Major Amputation 7 2.1 Total 29 6.7

Rotarex mechanical debulking in In-stent procedures: Clinical Follow-up: 12 months Results Major Adverse Events (MAE) after 12 month MAE Events (%) Death 31 9.2 MI 7 2.1 TLR 43 12.7 TVR 27 7.9 Major Amputation 13 3.8

Rotarex mechanical debulking in In-stent procedures: Clinical Follow-up: 12 months Results Major Adverse Events (MAE) after 12 month MAE Events (%) Death 31 9.2 MI 7 2.1 TLR 43 12.7 TVR 27 7.9 Major Amputation 13 3.8

Schmidt LINC 2013 Leipzig Rotarex + DCB Registry (39% ISR) Rotarex + DCB Freedom from restenosis DCB only Days follow-up

Rotarex mechanical debulking in In-stent procedures Summary Mechanical debulking with the Rotarex-catheter resulted in a high procedural success rate of 96.4% The low rate of procedural complications and 30 day clinical events supports the safety of the device The 12-months TLR rate of 12.7% in a real world scenario demonstrates the clinical effectiveness of Rotarex mechanical debulking for In-stent procedures

Rotarex mechanical debulking in In-stent procedures Summary The removal of stent-occluding material with the Rotarex before adjunctive therapy (DCB) appears to be a reasonable approach

Thank you!